418 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
AZN Astrazeneca PLC $37.56 $95.16B Downtrend
Article Searches
AstraZeneca, Starpharma Ink Drug Delivery Technology Deal http://www.zacks.com/stock/news/189148/astrazeneca-starpharma-ink-drug-delivery-technology-deal?cid=CS-ZC-FT-189148 Sep 07, 2015 - straZeneca (AZN) inks a drug delivery technology deal with Starpharma Holdings Limited for the development of oncology compounds.
AstraZeneca's Brilinta Gains FDA Nod for Label Expansion http://www.zacks.com/stock/news/189100/astrazenecas-brilinta-gains-fda-nod-for-label-expansion?cid=CS-ZC-FT-189100 Sep 04, 2015 - AstraZeneca (AZN) gained FDA approval for a new 60 mg dose for the treatment of patients with a history of heart attack beyond the first year.
AstraZeneca Ties Up for FluMist, CAZ-AVI Scores; Shares Up http://www.zacks.com/stock/news/188840/astrazeneca-ties-up-for-flumist-caz-avi-scores-shares-up?cid=CS-ZC-FT-188840 Sep 03, 2015 - AstraZeneca (AZN) signs up with Daiichi Sankyo for FluMist Quadrivalent in Japan; reports positive phase III data on antibiotic drug CAZ-AVI.
Nektar Receives $40M Milestone Payment from AstraZeneca http://www.zacks.com/stock/news/188836/nektar-receives-%2440m-milestone-payment-from-astrazeneca?cid=CS-ZC-FT-188836 Sep 03, 2015 - Nektar (NKTR) received milestone payment of $40 million from AstraZeneca (AZN) for the first commercial sale of Moventig in EU.
AstraZeneca Strikes Deal with Valeant for Psoriasis Drug http://www.zacks.com/stock/news/188754/astrazeneca-strikes-deal-with-valeant-for-psoriasis-drug?cid=CS-ZC-FT-188754 Sep 02, 2015 - AstraZeneca (AZN) strikes a collaboration agreement with Valeant for the development and commercialization of brodalumab.
Eli Lilly's (LLY) Diabetes Drug Synjardy Gets U.S. Approval http://www.zacks.com/stock/news/188169/eli-lillys-lly-diabetes-drug-synjardy-gets-us-approval?cid=CS-ZC-FT-188169 Aug 28, 2015 - Eli Lilly (LLY) announced that the FDA has approved its diabetes drug, Synjardy, for the treatment of patients with type II diabetes.
Medivation to Gain Global Rights to BioMarin's Talazoparib http://www.zacks.com/stock/news/187687/medivation-to-gain-global-rights-to-biomarins-talazoparib?cid=CS-ZC-FT-187687 Aug 25, 2015 - Medivation (MDVN) enters into an asset purchase agreement with BioMarin to acquire worldwide rights to BioMarin's talazoparib.
AstraZeneca, Peregrine Team Up for Immuno-Oncology Study http://www.zacks.com/stock/news/187678/astrazeneca-peregrine-team-up-for-immuno-oncology-study?cid=CS-ZC-FT-187678 Aug 25, 2015 - AstraZeneca (AZN) inked a clinical trial collaboration with Peregrine to evaluate bavituximab plus durvalumab in a phase I/Ib study.

Pages: 1...373839404142

<<<Page 42